WO2010024594A2

WO2010024594A2 - Composition for preventing or relieving obesity or diabetes

Info

Publication number: WO2010024594A2
Application number: PCT/KR2009/004775
Authority: WO
Inventors: 김민선; 이진희
Original assignee: 씨제이 제일제당㈜
Priority date: 2008-08-27
Filing date: 2009-08-27
Publication date: 2010-03-04
Also published as: WO2010024594A3; KR20100025299A

Abstract

The present invention provides a composition for preventing or relieving obesity or diabetes, and medicines or health foods containing the composition. The composition comprises 75-85 parts by weight of Garcinia cambogia extract, 15-25 parts by weight of soy peptides, and 0.5-5 parts by weight of L-carnitine.

Description

Composition for preventing or improving obesity or diabetes

The present invention relates to a composition for preventing or ameliorating obesity and / or diabetes, and specifically including garcinia cambogia extract, soy peptide, and L-carnitine in specific ratios to prevent or improve very good obesity and / or diabetes. The present invention relates to a health functional food comprising a composition and a composition thereof.

There are more than 20 billion fat cells in the human body, and if the supply is much higher than the energy demand in the human body, they are stored as triglycerides in the fat cells and decomposed into free fatty acids and glucose when energy is depleted. Is used. About 30-40% of modern people have obesity, which is caused by excessive energy accumulation due to the imbalance of this process, which results in the increase or increase in the size of fat cells.

This obesity is very closely related to the development of various adult diseases, the higher the obesity, the higher the prevalence of diabetes, cholelithiasis, hypertension, heart disease and stroke. In general, the increase in body fat shows a decrease in insulin sensitivity, obesity is known as one of several causes of diabetes.

The most reasonable way to treat this obesity is to consume all the nutrients while limiting calories. The use of calorie-restricted foods generally severely restricts meals, causing problems such as attachment to foods, nutrient imbalances, and eating more after weight loss. It is necessary to develop a realistic way to reduce body weight by adjusting the amount of food while receiving functional foods or functional supplements to help all the nutrients evenly and treat obesity without side effects.

Considering that obesity is the cause of various adult diseases, including diabetes, it is more important to reduce body fat than to lose weight. Reducing body fat requires a reduction in fat accumulated in the body due to reduced calorie intake and increased calorie consumption. Functional foods used to reduce body fat have a combination of anti-obesity effects, such as inhibiting the absorption of fat supplied in the diet, promoting the breakdown of fat, and inhibiting the synthesis of nutrients derived from excess sugar into the body fat. Would be more effective. However, simply mixing a single ingredient that has been found to be effective in the past does not have an anti-obesity effect or a synergistic effect, and may even alleviate the effect or exhibit a deleterious effect.

Garcinia cambogia is a tropical fruit tree of the family Guttiferae, which is native to Southeast Asia, including India. Garcinia cambogia extract is made from powdered extract of Garcinia cambogia fruit. Garcinia cambogia extract contains 10-30% (dry weight) of hydroxy citric acid (HCA) and is very similar to citric acid in citrus fruits such as oranges and lemons, but it is common in nature with hydroxyl groups. It is not a substance. HCA inhibits the conversion of citrate to acetyl-Co-A in vivo, which inhibits the synthesis of fatty acids, promotes oxidation, and converts it into glucogen synthesis, which increases energy production as well as suppressing appetite and lipolysis. It is known to have various bioactive functions such as promoting. In addition, it is known to have no toxic or tolerant origin from natural foods and no side effects such as insomnia, neuroanxiety, and depression that occur in other appetite suppressants.

To improve the physiological functions of soy protein in the early 1980s, such as cholesterol lowering effect and to make simpler intake form, soy protein has solubility and low aqueous solution viscosity, soy protein has physiological function and amino acid score 100 Low molecular soybean peptides have been developed that have fast absorption rates without falling below. Soybean peptides are known as hydrolysates of soy protein, which activate the sympathetic nervous system in the body to inhibit the absorption of fat, inhibit the rise of blood cholesterol and triglycerides, and exert body fat decomposition effects. In addition, it has been reported to be effective for muscle enhancement and fat reduction through human testing (Hyung-Ju Lee, Korean Soybean Research Journal 15 (1): 16-22, 1998).

L-carnitine is essential for fatty acid oxidation and energy production, and there is a risk of fatty acid accumulation in the cytoplasm when L-carnitine deficiency results in peroxidation. Long-chain fatty acids, a kind of fatty acid products, are mainly oxidized in the mitochondrial matrix and used as energy. The long-chain fatty acids bind with carnitine to be acylcarnitine, which makes it possible to pass through the inner membrane of the mitochondria. Thus, supplementation of carnitine is known to promote body fat breakdown. L-carnitine has also been shown to promote the burning of body fat by increasing the expression of carnitine palmitoyltransferase-1 (CPT-1) gene, a key enzyme in fatty acid degradation pathways (Korean Patent Publication No. 2004-0083874). It is known to have a fat decomposition effect and a cellulite removal effect (Korean Patent Publication 2005-0067837). In addition, L-carnitine is known to be effective in lowering blood triglyceride and cholesterol concentrations, preventing cardiovascular diseases, controlling glucose metabolism and losing weight.

However, each of these components did not have a sufficient effect on reducing obesity and reducing blood sugar through body fat reduction, it is necessary to develop a composition for preventing or improving obesity and diabetes having a better effect.

Technical challenges

Accordingly, the present inventors have recognized the necessity of developing a composition for the prevention or improvement of obesity and diabetes, and researched a composition for the prevention or improvement of obesity and diabetes having a better effect, Garcinia cambogia, soybean peptide, and L- Carnitine in a specific composition ratio has been found to have a significant body fat reduction effect and blood sugar reduction effect unpredictable to those skilled in the art to complete the present invention.

Accordingly, it is an object of the present invention to provide a composition for the prevention or improvement of obesity or diabetes, which contains garcinia cambogia, soy peptide and L-carnitine in a very effective composition ratio in the effect of reducing body fat and reducing blood sugar.

Another object of the present invention is to provide a composition for the prevention of diseases caused by obesity or diabetes, including garcinia cambogia, soybean peptide, and L-carnitine in a very effective composition ratio.

Still another object of the present invention is to provide a pharmaceutical product and a dietary supplement comprising the composition.

Technical solution

In order to achieve the above object, the present invention provides a composition for preventing or improving obesity or diabetes, including 75 to 85 parts by weight of Garcinia cambogia extract, 15 to 25 parts by weight of soybean peptide, and 0.5 to 5 parts by weight of L-carnitine. .

The present invention also provides a composition for the prevention of cholestasis, hypertension, heart disease, or stroke comprising 75 to 85 parts by weight of Garcinia cambogia extract, 15 to 25 parts by weight of soybean peptide, and 0.5 to 5 parts by weight of L-carnitine. .

The present invention also provides a medicament comprising the composition and a pharmaceutically acceptable carrier or additive.

The present invention also provides a dietary supplement comprising the composition and a food acceptable carrier or additive.

Hereinafter, the present invention will be described in more detail.

The composition for preventing or improving obesity or diabetes according to the present invention is 75 to 85 parts by weight of each of Garcinia cambogia extract, soybean peptide, and L-carnitine, each of which has been known to reduce body fat in a specific ratio, that is, Garcinia cambogia extract. 15 to 25 parts by weight of soybean peptides and 0.5 to 5 parts by weight of L-carnitine have been found to have a remarkable effect on body fat reduction and blood sugar reduction effects that are unpredictable to those skilled in the art compared to other proportions. It is.

Therefore, in one aspect, the present invention provides a composition for preventing or improving obesity or diabetes, comprising 75 to 85 parts by weight of Garcinia cambogia extract, 15 to 25 parts by weight of soybean peptide, and 0.5 to 5 parts by weight of L-carnitine. . The composition for preventing or improving obesity or diabetes may preferably comprise 78 to 80 parts by weight of Garcinia cambogia extract, 18 to 21 parts by weight of soybean peptide, and 1 to 2 parts by weight of L-carnitine, most preferably Garcinia 78.95 parts by weight of cambogia extract, 19.74 parts by weight of soy peptide, and 1.31 parts by weight of L-carnitine.

The composition for preventing or improving obesity or diabetes is effective in preventing cholecystosis, hypertension, heart disease, or stroke due to obesity or diabetes due to the prevention or improvement effect of obesity or diabetes.

Thus, in another aspect, the present invention is to prevent cholestatic, hypertension, heart disease, or stroke comprising 75 to 85 parts by weight of Garcinia cambogia extract, 15 to 25 parts by weight of soy peptide, and 0.5 to 5 parts by weight of L-carnitine It provides a composition for.

The garcinia cambogia extract can be directly extracted and powdered using the rind of the fruit of the garcinia cambogia, or can be obtained by using a commercially available extract (Interhealth Nutraceuticals, Benicia, CA, USA).

The soybean peptide is a hydrolyzate of soy protein, can be prepared according to a method known to those skilled in the art, and can be obtained by using a commercially available soybean peptide (Fuji Oil , Japan). The L-carnitine is biosynthesized in normal liver or kidney of a living body, and is contained in red meat, dairy products, nuts and the like. L-carnitine may be extracted from these natural natural substances, may be produced synthetically, or may be produced by microbial fermentation. In addition, commercially available L-carnitine can be obtained and used (Lonza, Swiss).

The composition for preventing or improving obesity or diabetes of the present invention may include other auxiliary ingredients in addition to the main component to further enhance the obesity or diabetes improving effect of the composition, even if there is no such effect anti-obesity or anti-diabetic effect If it does not inhibit it may further contain additional auxiliary ingredients in consideration of taste, palatability, shelf life and the like. Such auxiliary ingredients include, but are not limited to, polydextrose, citric acid, malic acid, liquid fructose, sugar, sugar alcohols, flavors, or mixtures thereof.

The specific proportion of the composition according to the present invention can be used for improving obesity or diabetes, and the prevention or improvement effect of obesity or diabetes is remarkably superior to compositions containing the same ingredients but in different proportions. This was demonstrated in the following examples, and specifically, as a result of administering to rats a certain proportion of the composition to support a specific proportion of the composition of the present invention, insulin, C-peptide, and leptin, hormones associated with obesity The level of was significantly reduced compared to other proportions of the composition, and the effect of restoring blood glucose levels to normal levels in rats with obesity was significant. Therefore, it can be seen that the composition of the specific composition ratio according to the present invention has a significantly higher effect of improving obesity and diabetes compared to other composition ratio compositions. Thus, the composition according to the present invention can also be used as a raw material of medicines for the prevention or improvement of obesity and diabetes. In addition, it can be used as a raw material of medicines for the prevention of various diseases caused by obesity and diabetes.

Thus, in another aspect, the present invention provides a medicament comprising the composition according to the present invention, and a pharmaceutically acceptable carrier or additive.

The medicament may be formulated in conventional pharmaceutical formulations known in the art. The medicament may be formulated and administered in any dosage form including, but not limited to, oral, injectable, suppository, transdermal, and non-administrative agents, but preferably liquids, suspensions, powders, granules, It may be formulated into a formulation for oral administration such as tablets, capsules, pills, or excipients.

When formulated into each of the above formulations, it may be prepared by the addition of a pharmaceutically acceptable carrier or additive necessary for the preparation of each formulation. Representatively, when formulated into a dosage form for oral administration, one or more of a diluent, a lubricant, a binder, a disintegrant, a sweetener, a stabilizer, and a preservative may be used as the carrier, and as an additive, flavors, vitamins, and antioxidants may be used. One or more types can be selected and used out of them.

The carrier and the additive may be any pharmaceutically acceptable, and specifically, a diluent may include lactose, corn starch, soybean oil, microcrystalline cellulose, or mannitol, and a lubricant may include magnesium stearate or talc, and a binder may be polyvinylpyrrolidone. Or hydroxypropyl cellulose is preferred. In addition, as a disintegrant, calcium carboxymethyl cellulose, sodium starch glycolate, potassium polyacrylic acid, or crospovidone, sweetener as white sugar, fructose, sorbitol, or aspartame, stabilizer as carboxymethyl cellulose sodium, beta-cyclodextrin, As lead, or xanthan gum, and preservative, methyl paraoxybenzoate, propyl paraoxybenzoate, or potassium sorbate is preferable.

In addition to the above ingredients, in order to enhance the taste as a known additive, natural flavors such as plum flavor, lemon flavor, pineapple flavor, herbal flavor, natural pigments such as natural fruit juice, chlorophyllin, flavonoid, fructose, honey, sugar alcohol, sugar Sweetening ingredients such as, or may be used by mixing an acidulant such as citric acid, sodium citrate.

In order to obtain an effect of preventing or improving obesity or diabetes, or preventing a disease caused by obesity or diabetes, the medicine has a total daily dose of 60 kg of the active ingredient of the composition. The dose may be administered several times to be 2280-4560mg, and may be appropriately increased or decreased depending on the age, sex, degree of obesity or diabetes, diet, and other drugs currently being taken.

The composition according to the present invention can also be used as a raw material of dietary supplement for the prevention or improvement of obesity and diabetes. In addition, it can be used as a raw material of health functional foods for the prevention of various diseases caused by obesity and diabetes.

Accordingly, the present invention in another aspect provides a dietary supplement comprising the composition according to the present invention and a food acceptable carrier or additive.

Such dietary supplements can be formulated in the formulation of conventional dietary supplements known in the art. The dietary supplement may be prepared, for example, as a powder, granules, tablets, capsules, suspensions, emulsions, syrups, liquids, extracts, teas, jelly, or beverages. As the food acceptable carrier or additive, any carrier or additive known to be usable in the art may be used to prepare a formulation to be prepared.

Medicines and health functional foods according to the present invention can be used for the prevention or improvement of obesity or diabetes, and the prevention of various diseases caused by obesity or diabetes with little side effects to the human body, as well as easy to take Can be used.

The pharmaceutical and dietary supplement according to the present invention may be simultaneously administered with Garcinia cambogia extract, soybean peptide, and L-carnitine, which are included as active ingredients, but may exhibit an anti-obesity or anti-diabetic effect of the composition. It may be administered sequentially at a predetermined interval within the range of. If the active ingredients of Garcinia cambogia extract, soybean peptide, and L-carnitine are to be administered at predetermined intervals, each active ingredient may be formulated in a separate, separate formulation. If the active ingredient of Garcinia cambogia extract, soybean peptide, and L-carnitine is to be administered at the same time, it may be formulated in a uniformly mixed form in one formulation, or may be formulated in separate formulations and then administered simultaneously. You may.

Favorable effect

As described above, the composition according to the present invention comprises a garcinia cambogia extract, soybean peptide, and L-carnitine in a specific range of ratios, thereby having a remarkably effective effect on the anti-obesity and anti-diabetic effects to those skilled in the art. Because it is made of natural materials, it has little side effects to the human body. Therefore, the composition according to the present invention can be used as a medicine or health functional food for the prevention or improvement of obesity or diabetes, and the prevention of various diseases caused by obesity or diabetes.

Best Mode for Carrying Out the Invention

Hereinafter, the present invention will be described in more detail with reference to the following examples. However, these examples are only for the understanding of the present invention, and the scope of the present invention is not limited by them in any sense.

실시예 1: 본 발명의 조성물의 제조 Example 1 Preparation of Compositions of the Invention

The garcinia cambogia extract, soy peptide and L-carnitine were weighed to a weight ratio of 78.95: 19.74: 1.31, and the sum of the weights of the three components was 1520 mg, dissolved in water to prepare 100 mL of a liquid.

비교예 1 Comparative Example 1

100 mL of the solution was prepared in the same manner as in Example 1 except that the garcinia cambogia extract, soybean peptide, and L-carnitine had a weight ratio of 16.4: 81.97: 1.63.

비교예 2 Comparative Example 2

100 mL of the solution was prepared in the same manner as in Example 1 except that the garcinia cambogia extract, soybean peptide, and L-carnitine had a weight ratio of 37.0: 61.73: 1.27.

실험예 1:　동물 시험 Experimental Example 1: Animal Test

1) Experiment Method

By using a dietary obese animal model that induces obesity by ingesting a high-fat diet in which dietary lipid content is 40% of total energy, the compositions of Examples 1 and Comparative Examples 1 and 2 improve obesity and lower blood sugar The effect on the was tested.

Specifically, five-week-old Sprague-Dawley species males were divided into eight groups of eight rats per group, adapted to the environment for one week while providing a solid feed, and then subjected to a normalized block design according to the randomized block design. 76 diet, n = 8), obesity induction control group, Example 1 administration group, Comparative Example 1 administration group, and Comparative Example 2 administration group. Then, the high fat diet added to the dietary lipid content to 40% of the total energy to be ingested by mixing with the composition at a 3.09 g / kg dietary dose, the normal group to provide a normal diet (solid feed), The obesity induction control group consumed the above-mentioned high-altitude diet of total energy. After eating this diet for a total of 9 weeks, the effect on obesity-related biomarkers was measured.

2) Experiment result

A. Epididymal fat cell size

The weight of visceral adipose tissue (dididymicular fat, perirenal fat, mesenteric fat and posterior cavity fat) collected for adipose tissue examination was measured. Some extracted epididymal and mesenteric adipose tissues were chopped into 0.1 mm ³ in a tissue culture dish containing 0.1 M phosphate buffer solution (100 ^mm diameter), and then 4% paraformaldehyde containing glutaraldehyde (1%). Fixed in solution for 24 hours. The tissues washed three times for 10 minutes with 0.1 M phosphate buffer solution were again fixed in 1% OsO ₄ (Osmium tetraoxide) solution for 30 minutes and fixed in 70%, 80%, 90% and 95% ethanol, respectively, for dehydration of the tissues. Dip by minute. After two additional dehydration cycles of 1 hour with 100% ethanol, the solution was immersed in Epon solution for 24 hours. The syringe was soaked in the newly prepared Epon solution for 24 hours. The newly prepared Epon solution was blocked using a syringe to prevent bubbles from forming on the tissue side, and after embedding, the sections were slideed. The resulting adipocyte slides were developed using an optical microscope (Axioplan 2, Zeiss, Gottingen, Germany) and a digital camera mounted on the microscope, and then the area of the tissue sections was detected by Discovery series Quantity One (Bio-Rad Laboratories, Inc., Hercules, CA, USA) program was used to determine the number of cells per unit area.

As a result, the results shown in Table 1 below.

TABLE 1

	혈중농도(평균) Blood concentration (average)
	정상군 Normal	비만유도 대조군 Obesity Induction Control	실시예 1 투여군 Example 1 Administration Group	비교예 1 투여군 Comparative Example 1 Administration Group	비교예 2 투여군 Comparative Example 2 Administration Group
부고환지방세포크기 ( ㎛²)Epididymal fat cell size (Μm ² )	3.97 ±0.08 3.97 ± 0.08	7.17 ±0.43^a* 7.17 ± 0.43 ^{a *}	4.64 ±0.22^c 4.64 ± 0.22 ^c	6.07 ±0.32^b 6.07 ± 0.32 ^b	5.99 ±0.38^b 5.99 ± 0.38 ^b

Different numbers in the same column represent significant differences between experimental groups at the p <0.05 level.

* Was significantly different at p <0.05 level compared to normal group by Student's t-test.

B. Triglyceride concentration in liver tissue

To extract lipid components of liver tissue, 2 ml of distilled water was added to 0.5 g of liver tissue according to the method of Folch et al. (1957), followed by polytron homogenizer (IKA-WERKE GmbH & Co., Ultra-Turrax, Staufen, Germany). Homogenized using. 5 ml of a chloroform: methanol solution (2: 1, v / v) was added to the homogenate, vortexed, and centrifuged at 1000 xg for 10 minutes to separate only the lower layer solution. 2 ml of chloroform: methanol solution (2: 1, v / v) was added to the remaining supernatant and the liver was separated completely by repeating the same procedure. 3 ml of a solution of chloroform: methanol: 0.05% CaCl ₂ (3:48:47, v / v / v) was added to the resulting lower layer, followed by vortexing for 1 minute, followed by centrifugation at 1000 xg for 10 minutes. The final lower layer solution was taken and completely dried with nitrogen gas, and then the total amount of lipid was measured. The dried lipids were dissolved in 1 ml of methanol and used for lipid analysis.

Triglyceride and cholesterol concentrations of hepatic lipid extracts were measured using the same commercial lipid analysis kit (Yongdong Pharm., Seoul, Korea) as used for serum lipid concentration analysis. Free fatty acid concentrations were measured by SICDIA NEFAZYME kit (Shinyang Chemical). , Seoul, Korea & Eiken Chemical, Tokyo, Japan).

The results are summarized in Table 2 below.

TABLE 2

	혈중농도(평균) Blood concentration (average)
	정상군 Normal	비만유도 대조군 Obesity Induction Control	실시예 1 투여군 Example 1 Administration Group	비교예 1 투여군 Comparative Example 1 Administration Group	비교예 2 투여군 Comparative Example 2 Administration Group
중성지방 (mg/g liver)Triglyceride (mg / g liver)	6.26 ±0.51 6.26 ± 0.51	15.9 ±0.29^a* 15.9 ± 0.29 ^{a *}	14.7 ±0.29^b 14.7 ± 0.29 ^b	15.9 ±0.21^a 15.9 ± 0.21 ^a	15.9 ±0.28^a 15.9 ± 0.28 ^a

* Was significantly different at p <0.05 level compared to normal group by Student's t-test

C. Measurement of Obesity-Related Hormone Levels

After ingesting a high fat diet for 9 weeks as described above, blood levels of the obesity-related hormones insulin, C-peptide, and leptin were measured. Insulin, C-peptide, and leptin concentrations were determined by Rat insulin RIA kit (LINCO Research, Inc, St. Charles, USA), Rat C-peptide RIA kit (LINCO Research, Inc, St.Charles, USA), and Rat Leptin, respectively. RIA kit (LINCO Research, Inc, St. Charles, USA) was used to measure by radioimmunoassay (RIA) by gamma-counter (COBRA 5010 Quantum, USA). RIA is a type of precipitation method in which an antibody is reacted with an antigen in a sample for a certain time and then reacted with a labeling antigen to the binding material.

The results are shown in Table 3 below.

TABLE 3

	혈중농도(평균) Blood concentration (average)
	정상군 Normal	비만유도 대조군 Obesity Induction Control	실시예 1 투여군 Example 1 Administration Group	비교예 1 투여군 Comparative Example 1 Administration Group	비교예 2 투여군 Comparative Example 2 Administration Group
인슐린(ng/ml) Insulin (ng / ml)	1.08 ±0.20 1.08 ± 0.20	3.38 ±0.88^a* 3.38 ± 0.88 ^{a *}	1.19 ±0.30^b 1.19 ± 0.30 ^b	2.42 ±0.39^ab 2.42 ± 0.39 ^ab	1.72 ±0.31^b 1.72 ± 0.31 ^b
C- 펩타이드(ng/ml) C-peptide (ng / ml)	2.12 ±0.18 2.12 ± 0.18	5.58 ±0.79^a* 5.58 ± 0.79 ^{a *}	2.50 ±0.40^b 2.50 ± 0.40 ^b	4.08 ±0.58^ab 4.08 ± 0.58 ^ab	3.31 ±0.44^b 3.31 ± 0.44 ^b
렙틴(uU/ml) Leptin (uU / ml)	3.04 ±0.31 3.04 ± 0.31	11.0 ±1.57^a11.0 ± 1.57 ^a	6.09 ±0.84^b 6.09 ± 0.84 ^b	8.71 ±1.51^ab 8.71 ± 1.51 ^ab	8.12 ±1.30^ab 8.12 ± 1.30 ^ab

According to the results of Table 3, in Example 1, Comparative Examples 1 and 2, a significant decrease in blood glucose concentration was observed compared to the obesity induction control. However, the composition administration group of Comparative Examples 1 and 2 was reduced by 28% and 49%, respectively, compared to the obesity induction control group, whereas the composition administration group of Example 1 was reduced by 65%, which is very significant compared to Comparative Examples 1 and 2. The concentration was reduced. In addition, in the case of C-peptide, the composition-administered group of Comparative Examples 1 and 2 was decreased by 27% and 41%, respectively, compared to the obesity-induced control group, whereas the composition-administered group of Example 1 was reduced by 55%, compared to Comparative Examples 1 and 2. Significantly decreased blood levels of C-peptide. In addition, in the case of leptin, the composition administration group of Comparative Examples 1 and 2 was reduced by 21% and 26%, respectively, compared to the obesity induction control group, whereas the composition administration group of Example 1 was reduced by 44% to a very significant degree compared to Comparative Examples 1 and 2. Blood levels of leptin were decreased. Therefore, the composition of Example 1 was found to be significantly superior in the effect of obesity compared to Comparative Examples 1 and 2.

D. Measurement of Blood Glucose Levels

After ingesting a high fat diet for 9 weeks as described above, blood glucose levels that could be indicators of diabetes improvement were measured. Blood glucose levels were measured using a biochemical automated analyzer (Express Plus, Chiron Diagnostics Co., USA), and an assay kit reagent was purchased from Bayer (Tarrytown, NY, USA).

As a result, the results shown in Table 4 below.

Table 4

	혈당 농도(mg/100ml) Blood glucose level (mg / 100ml)
	정상군 Normal	비만유도 대조군 Obesity Induction Control	실시예 1 투여군 Example 1 Administration Group	비교예 1 투여군 Comparative Example 1 Administration Group	비교예 2 투여군 Comparative Example 2 Administration Group
혈당 Blood sugar	159.0 ±5.14 159.0 ± 5.14	193.6 ±11.0^a* 193.6 ± 11.0 ^{a *}	145.4 ±8.08^c 145.4 ± 8.08 ^c	183.9 ±7.59^b 183.9 ± 7.59 ^b	167.3 ±5.41^bc 167.3 ± 5.41 ^bc

According to the results of Table 4, in Example 1, Comparative Example 2 was observed a significant decrease in blood glucose concentration compared to the obesity induction control. However, the composition administration group of Comparative Example 2 was reduced by 14% compared to the obesity induction control group, while the composition administration group of Example 1 was reduced by 25% compared to Comparative Example 2 to a very significant reduction in blood glucose concentration. Therefore, the composition of Example 1 was found to be significantly superior in diabetic improvement compared to Comparative Example 2. From these results, it can be seen that the composition according to the present invention can help to maintain a fasting blood sugar level at an overweight person.

실험예 2: 임상시험 Experimental Example 2: Clinical Trial

140 women (19-50 years old) with BMI 25-29.9 kg / m2 were randomly divided into two groups, 70 for each of the experimental group and two of the control group. In the liquid preparation prepared in Example 1, the control group was to consume only the medium used in Example 1 as a control solution for 8 weeks at 100 mL per day for 30 minutes before meals. Changes in various weight control-related biomarkers were evaluated after 8 weeks of ingestion of the solution or control solution of Example 1.

A total of 140 subjects were enrolled, and a total of 114 subjects (61 experimental groups, 53 control groups) were completed. The analysis was performed on 114 subjects who completed this study.

There were no significant differences in the demographic characteristics, lifestyle, and dietary habits between the control and experimental groups. All subjects were encouraged to eat 500 kcal / day for the duration of the trial and were evaluated at 76% to 95% of the recommended calorie reduction. There were no significant differences in calories and all nutrient intakes of subjects examined at weeks 0, 4, and 8.

As a result of the efficacy evaluation, the weight of the test group and the control group decreased by 1.74 kg and 1.01 kg, respectively. The test group and the control group showed a significant decrease in the group, and the test group showed a significant decrease compared to the control group (p <0.001). Body mass index (BMI) also showed a significant decrease in the 0.67 kg / m ² group in the test group and 0.39 kg / m ² group in the control group and a significant decrease in the test group (p <0.001). In fat (kg) measured by BIA, the test group showed a significant decrease of 1.38kg and the control group 0.86kg, respectively, and the test group showed a statistically significant decrease compared to the control group (p <0.001). Fat (%) measured by BIA showed a significant decrease of 1.19% in the test group and 0.79% in the control group, respectively (p <0.001).

Fat (%) measured by DEXA (Dual Energy X-ray Absorptiometry) decreased by 0.26% in the test group and 0.3% in the control group.

As a result of site-specific DEXA analysis, the control group increased 0.01% in the tissue tissue fat (%), whereas the experimental group decreased by 0.78%, and it was statistically significant in the test group (p = 0.0195). In the leg tissue tissue (g), 380.97g was decreased in the test group and 66.06g in the control group, which was more decreased than the control group (p = 0.0194).

As a result of analyzing the body fat in the trunk area, the control group increased 0.39% in the tissue fat (%), while the test group decreased by 0.53%, and the test group showed a significant decrease of p <0.1.

In the safety evaluation, most of the items including blood test, hemochemical test, blood pressure, and pulse rate showed no significant difference between the two groups before and after the experiment.

In conclusion, according to the clinical trial results of the composition according to the present invention in obese people, it can be said that it is safe and effective in reducing body weight and fat mass.

Claims

Garcinia cambogia extract 75 to 85 parts by weight, soybean peptide 15 to 25 parts by weight, and L-carnitine 0.5 to 5 parts by weight of the composition for the prevention or improvement of obesity or diabetes.
According to claim 1, wherein the garcinia cambogia extract is 78 to 80 parts by weight, soybean peptide is 18 to 21 parts by weight, L-carnitine composition, characterized in that it comprises 1 to 2 parts by weight.
Garcinia cambogia extract 75 to 85 parts by weight, soybean peptide 15 to 25 parts by weight, and L- carnitine 0.5 to 5 parts by weight of the composition for the prevention of cholelithiasis, hypertension, heart disease, or stroke.
The composition according to any one of claims 1 to 3, further comprising polydextrose, citric acid, malic acid, liquid fructose, sugar, sugar alcohols, fragrances, or mixtures thereof.
A pharmaceutical product comprising the composition according to any one of claims 1 to 3 and a pharmaceutically acceptable carrier or additive.
6. A pharmaceutical product according to claim 5 in the form of a powder, granule, tablet, capsule, suspension, emulsion, syrup, liquid, aerosol, extract, injection, transdermal or suppository.
A health functional food comprising the composition according to any one of claims 1 to 3 and a food acceptable carrier or additive.
The health functional food according to claim 7, wherein the liquid, suspension, powder, granule, tablet, capsule, pill, extract, tea, jelly, or beverage is in the form of.